Company intelligence
MedChemExpress LLC
Master of Bioactive Molecules.
About MedChemExpress LLC
MedChemExpress (MCE) is a leading global supplier of life science reagents, dedicated to providing innovative solutions for scientific research and drug development. We offer a comprehensive range of high-quality active molecules, including inhibitors, compound libraries, recombinant proteins, antibodies, and more, positioning itself as a leading global supplier of research chemicals and bioactive compounds. Headquartered in New Jersey, USA, MCE has established multiple R&D, production, and logistics centers worldwide. With a team of seasoned experts, MCE has built an end-to-end service system, encompassing services such as HNMR data analysis, bioactivity evaluation, technical consultation, and after-sales support. Backed by stringent management systems and quality control standards, MCE delivers efficient, precise, and reliable services to over 15,000 research institutions worldwide. Committed to driving innovation in drug discovery, MCE is your trusted long-term partner for scientific exploration and pharmaceutical research. https://linktr.ee/MedChemExpress
Verified activity
Signals from MedChemExpress LLC
14 published signals
Research & Knowledge
MedChemExpress LLC reported that in a Phase 3 trial, Avexitide reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% vs. placebo in 78 participants, meeting all secondary endpoints.
Reported by MedChemExpress LLC
Research & Knowledge
MedChemExpress LLC published an article tracing the molecular cascade driven by Aβ from production and aggregation to neuronal and synaptic dysfunction.
Reported by MedChemExpress LLC
Research & Knowledge
MedChemExpress LLC published a study finding that mutant KRAS can reshape the tumor microbiome and enrich Bacteroides acidifaciens.
Reported by MedChemExpress LLC
Research & Knowledge
MedChemExpress LLC notes that muscle stem cells and their niche may play a key role in impaired muscle regeneration.
Reported by MedChemExpress LLC
Research & Knowledge
MedChemExpress LLC notes that Utrophin is being explored as a potential substitute for dystrophin, including CRISPR/Cas9-based approaches to boost its expression.
Reported by MedChemExpress LLC
Research & Knowledge
MedChemExpress LLC notes that ANXA11 emerged as a potential therapeutic target with its suppression improving muscle function in DMD mice.
Reported by MedChemExpress LLC
Presence & Recognition
MedChemExpress LLC hosted the 2026 MCE Impact Taiwan Symposium on precision screening and innovative drug discovery at the Taipei Bioinnovation Park on Thursday, November 12, 2026.
Reported by MedChemExpress LLC
Research & Knowledge
MedChemExpress LLC researchers used GluePCA to identify ~210 zinc fingers that bind to CRBN–pomalidomide and combined that with AI-based MaSIF-mimicry to map potential CRBN interactions across the proteome.
Reported by MedChemExpress LLC
Presence & Recognition
MedChemExpress LLC hosted an event discussing compound libraries, custom synthesis, and medicinal chemistry.
Reported by MedChemExpress LLC
Legal & Regulatory
MedChemExpress LLC notes that the FDA approved Zanvastro from Ionis Pharmaceuticals, Inc. as the first FDA-approved treatment for Alexander disease and the first therapy to directly target the disease’s underlying mechanism on September 3, 2026.
Reported by MedChemExpress LLC
Legal & Regulatory
MedChemExpress LLC reported that Oveporexton was approved as a direct orexin signaling restoration agent for narcolepsy type 1 in August 2026.
Reported by MedChemExpress LLC
Legal & Regulatory
MedChemExpress LLC reported that Iberdomide advances the CEMoD/E3 ligase modulation and garetosmab targets Activin A and brepocitinib targets JAK/TYK2 in August 2026.
Reported by MedChemExpress LLC
Legal & Regulatory
MedChemExpress LLC reported that Daraxonrasib was approved as a first-in-class RAS inhibitor for metastatic pancreatic cancer in August 2026.
Reported by MedChemExpress LLC
Legal & Regulatory
MedChemExpress LLC reported that Rusfertide was approved as a hepcidin mimetic for polycythemia vera in August 2026.
Reported by MedChemExpress LLC